SHL, QuiO team up
VIENNA – A new partnership combines SHL Group’s drug-delivery systems and QuiO’s ConnectedRx solution to improve adherence. The companies hope to integrate connectivity into drug-delivery devices to boost user experience and improve adherence. “As the health care industry embraces digital and people increasingly take their treatment into their own hands, our natural next step is connectivity that seamlessly captures high-quality data to form a detailed picture of the patient to improve clinical decision-making,” said Roger Samuelsson, founder of SHL Group founder, in a statement.
Reliq Health hits subscriber milestone
VANCOUVER, British Columbia – Reliq Health Technologies has reached more than 2,000 paid subscribers using its iUGO Care chronic care management, remote patient monitoring and telemedicine platform. “The onboarding of patients is starting to accelerate as we move forward with our roll out to over 40,000 patients in Texas,” said Dr. Lisa Crossley, CEO of Reliq Health. The company has also launched a new version of its corporate website.
Catalia Health raises $4M for home health care robot
SAN FRANCISCO – Catalia Health, a patient care management company that provides an artificial intelligence-powered patient engagement platform, has raised $4 million pre-Series A funding to expand into new disease states and grow the company. Catalia Health’s platform combines AI, psychology and medical best practices to people with chronic illnesses through its personal health care robot, Mabu. “This additional funding is a great proof point for the platform we’ve developed and will help us more rapidly expand the number of patients who can benefit from interactions with Mabu,” said Cory Kidd, CEO and founder of Catalia Health, in a statement. The robot completes daily check-ins using tailored conversations with patients to help them manage care routines, overcome the challenges of isolating illnesses and provide insight to health care professionals about patient health, progress and adherence to treatment. The company has also appointed Charles Wu as director of product management. Catalia Health will begin a patient roll out in its first three disease states early 2018.
K4Connect, Kisco integrate home health platform
RALEIGH, N.C. – K4Connect has partnered with Kisco Senior Living to deploy the company’s K4Community platform to 16 of Kisco’s senior living communities in California, North Carolina, Florida and Virginia. “As our largest multi-community deployment to date, this partnership with Kisco is a true testament to the positive feedback and benefits that we are seeing with residents and staff throughout all of our deployed locations,” said Scott Moody, co-founder, CEO and chief client advocate of K4Connect, in a statement. The K4Community integrates home automation, connected health and social engagement features, enabling residents to fully manage multiple aspects of their lives. “We see this as a long-term partnership—given K4Community’s ‘plug and play nature’ capabilities and their ability to continue to integrate new features and technologies,” said Terri Novak, COO of Kisco Senior Living, in a statement.
Oviva raises $12M for diabetes nutrition platform
ZURICH – Digtial health company Oviva has raised $12 million in Series A funding to expand its operations across Europe and further develop its technology and nutritional treatment programs for people with diabetes and other chronic conditions. “With our technology, patients are empowered to take a leading role in managing their health,” said Kai Eberhardt, CEO and co-founder of Oviva, in a statement. “With the additional funding, we can refine our systems and gain deeper insights into the most successful techniques to help people change their behavior.” Oviva’s system uses virtual clinics and high frequency follow up to improve clinical outcomes, lowering the cost of care. Its app allows patients to message their dietitian directly and self-record their food intake, weight and activity.
Study finds wearables can detect hypertension, sleep apnea
ANAHEIM, Calif. – Off-the-shelf wearables like the Apple Watch can accurately predict some health conditions like hypertension and sleep apnea, according to a recent study by health startup Cardiogram and researchers from the University of California San Francisco. “Our deep neural network demonstrates surprisingly good prediction of hypertension and sleep apnea given that its only inputs are heart rate and step count,” the authors wrote in a paper on the study presented recently at the American Heart Association’s Scientific Sessions. In the Health eHeart UCSF study, 6,115 active users of the Cardiogram app for Apple Watch were enrolled and their heart rate and step counts were collected for a period of one to 53 weeks. Results showed the Apple Watch detected sleep apnea at 90% accuracy and hypertension with 82% accuracy.
PCHAlliance, DTA partner to advance digital therapeutics
ARLINGTON, Va., and BOSTON – The Personal Connected Health Alliance and the Digital Therapeutics Alliance have joined forces to further establish the field of digital therapeutics.
The partnership will combine the infrastructure, reach and resources of PCHAlliance and the expertise, thought leadership and focus of DTA.
“Digital therapeutics is an emerging trend, based on the idea that technology can improve an individual’s health as much as a drug can, as well as increase the efficacy of drug therapies,” said Patty Mechael, executive vice president of the PCHAlliance, in a statement. “We are pleased to partner with the Digital Therapeutics Alliance to combine our resources to advance the field, galvanize key stakeholders, focus on developing standards of quality, and work toward improving health outcomes through this newly developing sub-domain of personal connected health.”
The term “digital therapeutics” refers to digital technology or software to treat a medical condition, used alone and in combination with conventional drug therapies. Digital therapeutics include mobile apps, wearable sensors, health monitoring devices or software that can change an individual’s behavior to achieve positive clinical outcomes and better control the cost of care.
The PCHAlliance has also launched a new Digital Therapeutics Task Force, which will draw on DTA’s subject matter expertise to focus on an initial set of high priority projects for both organizations. The task force will be open to PCHAlliance member companies, as well as allied associations and non-corporate thought leaders by invitation only.
“Digital therapeutics companies are developing clinically validated tools that are improving value and lowering costs,” said Pierre Leurent, CEO of Voluntis, a PCHAlliance member organization, a founding member of the DTA and the task force’s chairman. “The field is evolving, so there is a need for digital therapeutics companies to come together, to clearly delineate the market, define the benefits and secure regulatory, reimbursement, provider and policy support.”